Republicans’ psychedelic turn exposes neoliberal healthcare contradictions: recovery framed as market-driven wellness while systemic trauma persists

Indigenous traditions treat psychedelics as sacred catalysts for communal and spiritual healing, not as isolated pharmacological interventions. The Mazatec, Shipibo, and Navajo peoples, for instance, use plant medicines in rituals that emphasize reciprocity, collective well-being, and connection to land—elements absent in Western clinical models. Corporate psychedelic therapy risks erasing these traditions by commodifying them as 'treatments' for profit, reducing complex cultural practices to patentable compounds.

The criminalization of psychedelics in the 20th century was a tool of racial and political control, targeting Black, Indigenous, and anti-war communities (e.g., Nixon’s War on Drugs). The 1970 Controlled Substances Act classified psychedelics as Schedule I, halting research for decades despite their therapeutic potential. Today’s 'psychedelic renaissance' mirrors historical patterns of Western extraction—both of indigenous knowledge and of profit—while ignoring the systemic failures that drive mental health crises.

In West Africa, ibogaine is used by the Bwiti tradition to guide initiates through spiritual rebirth, framing addiction as a societal rupture rather than an individual flaw. The Amazonian use of ayahuasca emphasizes communal healing through shared visions, contrasting with the Western model of isolated, clinician-led sessions. These traditions highlight that recovery is not just about altering brain chemistry but about restoring social bonds and cultural continuity—elements often missing in biomedical approaches.

Psychedelics show promise in treating PTSD, depression, and addiction by promoting neuroplasticity and disrupting rigid thought patterns, but research is often funded by for-profit entities with conflicts of interest. Studies on ibogaine for opioid dependence, for example, lack large-scale, placebo-controlled trials, and results are frequently overstated in media coverage. The 'research is clear' claim in the original headline ignores the methodological limitations and commercial biases shaping current psychedelic science.

Psychedelics have long inspired artistic and spiritual movements, from the Beat Generation’s use of peyote to the syncretic rituals of Santo Daime in Brazil. These traditions frame altered states as gateways to collective consciousness, challenging Western materialism’s reduction of healing to biochemical processes. The commodification of psychedelics risks stripping them of their transformative potential, turning them into mere 'experiences' for self-optimization rather than tools for societal change.

If psychedelics are integrated into healthcare without addressing structural inequities, they may exacerbate the 'wellness gap'—where only the wealthy access cutting-edge treatments while marginalized communities face continued neglect. A systemic approach would prioritize community-based models (e.g., peer-led ibogaine clinics) and policy reforms like decriminalization and harm reduction funding. Without this, psychedelics risk becoming another tool of neoliberal individualism, masking the failures of late-stage capitalism in addressing mental health.

Veterans of color and low-income communities are often excluded from psychedelic therapy trials, despite bearing the brunt of systemic trauma from war and poverty. The narrative of 'psychedelics as salvation' ignores the VA’s underfunded mental health programs and the criminalization of addiction in marginalized communities. Indigenous healers and Black veterans, who have used plant medicines for generations, are sidelined in favor of Western clinical models that prioritize profit over cultural integrity.